Apraklonidin
Apraklonidin (Iopidine) je simpatomimetik koji se koristi u terapiji glaukoma. On je agonist α2-adrenergičkog receptora i slab agonist alfa-1 adrenergičkog receptora.
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| 2,6-dihloro-N- (4,5-dihidro-1H-imidazol-2-il) benzen-1,4-diamin | |||
| Klinički podaci | |||
| Robne marke | Iopidine | ||
| AHFS/Drugs.com | Monografija | ||
| MedlinePlus | a608005 | ||
| Identifikatori | |||
| CAS broj | 66711-21-5 | ||
| ATC kod | S01EA03 | ||
| PubChem[1][2] | 2216 | ||
| DrugBank | DB00964 | ||
| ChemSpider[3] | 2130 | ||
| UNII | 843CEN85DI 
| ||
| KEGG[4] | D07461
| ||
| ChEBI | CHEBI:2788
| ||
| ChEMBL[5] | CHEMBL647
| ||
| Hemijski podaci | |||
| Formula | C9H10Cl2N4 | ||
| Mol. masa | 245,108 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakokinetički podaci | |||
| Vezivanje za proteine plazme | 98,7% | ||
| Poluvreme eliminacije | 8 sata | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | Rx only | ||
| Način primene | Ofthalmički rastvor | ||
Apraklonidin se administrira u koncentraciji od 1% za sprečavanje i tretman povišenog posthirurškog intraokularnog pritiska i 0.5% za kratkotrajnu adjunktivnu terapiju kod pacijenata na maksimalno tolerisanoj medicinskoj terapiji kojima je neohodna dodatna redirekcija intraokularnog pritiska. Jedna kap se obično dodaje jedan sat pre laserske operacije oka i još jedna kap nakon završetka procedure.
Reference
uredi- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
Literatura
uredi- Chen P, Chen J, Lu D, Chen Y, Hsiao C (2006). „Comparing efficacies of 0.5% apraclonidine with 4% cocaine in the diagnosis of horner syndrome in pediatric patients”. J Ocul Pharmacol Ther 22 (3): 182–7. DOI:10.1089/jop.2006.22.182. PMID 16808679.
- Aslanides l, Tsiklis N, Ozkilic E, Coskunseven E, Pallikaris l, Jankov M (2006). „The effect of topical apraclonidine on subconjunctival hemorrhage and flap adherence in LASIK patients”. J Refract Surg 22 (6): 585–8. PMID 16805122.
- Koc F, Kansu T, Kavuncu S, Firat E (2006). „Topical apraclonidine testing discloses pupillary sympathetic denervation in diabetic patients”. J Neuroophthalmol 26 (1): 25–9. DOI:10.1097/01.wno.0000204648.79744.71. PMID 16518162.
- Garibaldi D, Hindman H, Grant M, Iliff N, Merbs S (2006). „Effect of 0.5% apraclonidine on ptosis in Horner syndrome”. Ophthal Plast Reconstr Surg 22 (1): 53–5. DOI:10.1097/01.iop.0000196322.05586.6a. PMID 16418668.
- Onal S, Gozum N, Gucukoglu A (2005). „Effect of apraclonidine versus dorzolamide on intraocular pressure after phacoemulsification”. Ophthalmic Surg Lasers Imaging 36 (6): 457–62. PMID 16355950.
